Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes

Marica Bordicchia, Antonella Pocognoli, Marco D'Anzeo, Walter Siquini, Daniele Minardi, Giovanni Muzzonigro, Paolo Dessì-Fulgheri, Riccardo Sarzani

Research output: Contribution to journalArticle

Abstract

Objectives: Most β-blockers may induce weight gain, dysglycemia, and dyslipidemia. Nebivolol is a third-generation β1-blocker with vasodilating properties mediated by β3 adrenergic receptors (β3AR). We investigated whether nebivolol is able to induce β3AR-mediated lipolysis, uncoupling protein 1 (UCP1), and size-reduction in human adipocytes. Methods: Human visceral (n=28) and subcutaneous adipose tissue (n=26) samples were used to obtain differentiated subcutaneous and visceral preadipocytes. Adipocytes were used to verify the effects of nebivolol onlipolysis, uncoupling protein 1 (UCP1) and other genes of the thermogenic program. Results: Lipolysis was induced by isoproterenol and specific β3AR agonist, as expected,and also by nebivolol at 100nmol/l and by its L-enantiomer at 10nmol/l (P

Original languageEnglish
Pages (from-to)389-396
Number of pages8
JournalJournal of Hypertension
Volume32
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • β3 adrenergic receptor
  • human adipocytes
  • nebivolol
  • uncoupling protein

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes'. Together they form a unique fingerprint.

  • Cite this